Intercept Pharma (ICPT) Misses Q4 EPS by 88c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals (ICPT) PT Lowered to $58 at Cantor Fitzgerald
February 14, 2018 11:25 AM ESTCantor Fitzgerald lowered its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $58.00 (from $69.00) while maintaining a Neutral rating.
Analyst Elemer Piros commented, "We are maintaining our Neutral rating and lowering our price target to $58 from $69, following adjustments to our model and reporting of... More
Intercept Pharmaceuticals (ICPT) PT Lowered to $57 at Wells Fargo
February 13, 2018 8:16 AM ESTWells Fargo lowered its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $57.00 (from $62.00) while maintaining a Market Perform rating.
... MoreIntercept Pharma (ICPT) Announces Phase 3 REVERSE Trial Evaluating OCA for Treatment of NASH Patients with Compensated Cirrhosis
February 12, 2018 8:05 AM ESTIntercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the REVERSE trial (Randomized Phase 3 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis). REVERSE is a randomized, double-blind, placebo-controlled, multi-center study that will evaluate the efficacy and safety of the investigational therapy obeticholic acid (OCA) in approximately 540 patients with a biopsy-confirmed diagnosis of cirrhosis due to NASH.
NASH is poised to soon eclipse hepatitis... More
